Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Insulin resistance in treated HIV infection.

Feeney ER, Mallon PW.

Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):443-58. doi: 10.1016/j.beem.2010.11.002. Review.

PMID:
21663838
2.

Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.

Shikuma CM, Day LJ, Gerschenson M.

Curr Drug Targets Infect Disord. 2005 Sep;5(3):255-62. Review.

PMID:
16181144
4.

Insulin resistance and HIV infection: a review.

Aboud M, Elgalib A, Kulasegaram R, Peters B.

Int J Clin Pract. 2007 Mar;61(3):463-72. Review.

PMID:
17313615
5.

Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy.

Dejkhamron P, Unachak K, Aurpibul L, Sirisanthana V.

J Pediatr Endocrinol Metab. 2014 May;27(5-6):403-12. doi: 10.1515/jpem-2013-0253.

PMID:
24259240
6.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
7.

Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.

Holstein A, Plaschke A, Egberts EH.

Exp Clin Endocrinol Diabetes. 2001;109(8):389-92. Review.

PMID:
11748485
8.

Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.

Samaras K.

J Antimicrob Chemother. 2008 Feb;61(2):238-45. Epub 2007 Dec 10. Review.

PMID:
18070830
9.

Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy.

Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, Hillon P, Portier H.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):245-50.

PMID:
11464143
10.

Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.

Leonard EG, McComsey GA.

Infect Dis Clin North Am. 2005 Sep;19(3):713-29. Review.

PMID:
16102657
11.

Metabolic complications of antiretroviral therapy in children.

Leonard EG, McComsey GA.

Pediatr Infect Dis J. 2003 Jan;22(1):77-84. Review.

PMID:
12544413
12.

Disorders of glucose metabolism in patients infected with human immunodeficiency virus.

Dubé MP.

Clin Infect Dis. 2000 Dec;31(6):1467-75. Epub 2000 Nov 29. Review.

PMID:
11096014
13.

Endothelial markers and HIV infection in the era of highly active antiretroviral treatment.

de Larrañaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA.

Thromb Res. 2003 May 1;110(2-3):93-8.

PMID:
12893023
14.

The metabolic puzzle during the evolution of HIV infection.

Salas-Salvadó J, García-Lorda P.

Clin Nutr. 2001 Oct;20(5):379-91. Review.

PMID:
11534932
15.

Metabolic complications of HIV-1 antiretroviral therapy: the lipodystrophy syndrome.

Borderi M, Verucchi G, Tadolini M, Spinosa S, Fortunato L, Talò S, Chiodo F.

New Microbiol. 2001 Jul;24(3):303-15. Review.

PMID:
11497090
16.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
17.

Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy.

Samaras K.

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):499-505. doi: 10.1097/QAI.0b013e31819c291b. Review.

PMID:
19223782
18.
19.

Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.

Vidal F, Domingo P, Viladés C, Peraire J, Arnedo M, Alcamí J, Leal M, Villarroya F, Gatell JM.

Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1365-82. doi: 10.1517/17425255.2011.621941. Review.

PMID:
21999362
20.

Supplemental Content

Support Center